A new study in Nature Communications uncovers how a sugar-binding protein, Galectin-3, can be harnessed to speed healing in diabetic foot ulcers — and how to bypass a major biochemical roadblock.**
Diabetic foot ulcers (DFUs) remain one of the most stubborn complications of diabetes — affecting up to 30% of patients, with recurrence rates approaching 65% within 3–5 years and a high risk of amputation and mortality. While angiogenesis (new vessel growth) is central to repair, it is often impaired in the diabetic wound bed.
The Engine: Galectin-3 and Integrin α5β1
Galectin-3 (Gal-3) is a carbohydrate-binding protein that, in healthy tissue, binds to the cell-surface receptor integrin α5β1. This triggers liquid–liquid phase separation (LLPS), clustering integrin molecules and activating focal adhesion kinase (FAK) — a key angiogenic signal. The result: new microvessels, stronger collagen deposition, and faster wound closure.
In diabetic skin, Gal-3 levels in the vasculature are reduced, impairing this regenerative cascade.
The Brakes: Advanced Glycation End-Products (AGEs)
The diabetic state brings excess AGEs — glycated proteins and lipids — that bind to Gal-3, blocking its interaction with integrin α5β1. This short-circuits angiogenic signaling and leaves wounds hypovascular and slow-healing.
The Fix: Local Galectin-3 Therapy
In Zhang et al.’s rodent models, topical recombinant Gal-3 in a hydrogel restored angiogenesis and accelerated healing — without worsening systemic insulin resistance. When combined with insulin, the benefits amplified: AGE levels in the wound fell, vessel density rose, and closure rates improved further.
Key findings include:
- Gal-3 directly binds integrin α5β1 to drive angiogenesis.
- AGEs competitively bind Gal-3, blocking this process.
- Local Gal-3 delivery bypasses systemic side effects.
- Co-delivery with insulin reduces AGE burden and synergizes healing.
Implications for DFU Care
This work reframes Gal-3 from a double-edged sword (linked to insulin resistance in some contexts) to a localized pro-healing signal when applied directly to the wound. It also suggests that dual-target strategies — enhancing Gal-3–integrin α5β1 signaling while reducing AGE load — could be a promising path for DFU management.
Reference:
Zhang Z, Zhao Z, Huang X, et al. Galectin-3–integrin α5β1 phase separation disrupted by advanced glycation end-products impairs diabetic wound healing in rodents. Nat Commun. 2025;16:7287. doi:10.1038/s41467-025-62320-w
Leave a Reply